Overview
Yunkwon Nam practices practicing medicine in Daejeon, Republic of Korea.
Nam is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Alzheimer's Disease, Dementia, and Neurotoxicity Syndromes.
They are actively involved in clinical research, co-authoring 39 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Yunkwon J. Nam
Is Yunkwon J. Nam a top-rated expert for Alzheimer's Disease?
MediFind is an objective health platform that identifies experts based on real-world data. Yunkwon J. Nam is classified as an Advanced expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Yunkwon J. Nam participate in research or clinical trials?
Yes. Yunkwon J. Nam has published 39 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Yunkwon J. Nam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Alzheimer's DiseaseNam isAdvanced. Learn about Alzheimer's Disease.
- DementiaNam isAdvanced. Learn about Dementia.
- Experienced
- Neurotoxicity SyndromesNam isExperienced. Learn about Neurotoxicity Syndromes.